JPRN-UMIN000015094已完成未知
PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC - LOGIK1401
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 17 人开始时间: 2014年9月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) known interstitial fibrosis or interstitial lung disease 2) Evidence of active malignancy 3) Brain metastasis with disordered consciousness 4) Uncontrolled Grade >/=3 SVC syndrome, pericardial effusion, pleural effusion, ascites 6) Active infectious disease 7) Concurrent radiotherapy including lung field
研究者
相似试验
已完成
2 期
A-LiquidJPRN-jRCT2080225060Department of Thoracic Oncology, National Cancer Center Hospital East25
招募中
2 期
Clinical Trial of Alectinib in Patients with ALK positive rare cancerRare cancers harboring ALK gene alterationsJPRN-jRCT2091220364ational Cancer Center Hospital26
已完成
2 期
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03155009Hoffmann-La Roche44
招募中
1 期
Alectinib Pharmacokinetic in Patients With NSCLCNon-small Cell Lung Cancer Stage IIIBALK Gene MutationNCT05713006Instituto Nacional de Cancerologia de Mexico45
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsALK Fusion-positive Solid or CNS TumorsNCT04774718Hoffmann-La Roche42